Cardiff Oncology (CRDF) Registration Filing summary

Company overview and business model

• Clinical-stage biotechnology company developing therapies targeting PLK1 inhibition for cancer treatment, focusing on RAS-mutated metastatic colorectal cancer (mCRC), metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC).

• Lead drug candidate, onvansertib, is an oral, highly selective PLK1 inhibitor with demonstrated safety and efficacy in early clinical trials and is being tested in combination with standard-of-care therapies.

• Clinical programs incorporate tumor genomics and biomarker assays to refine patient response assessment.

Financial performance and metrics

• As of February 20, 2025, 66,524,294 shares of common stock were issued and outstanding; authorized capital includes 150,000,000 shares of common stock and 20,000,000 shares of preferred stock.

• Net tangible book value as of December 31, 2024, was $82.9 million ($1.25 per share); after the offering, as adjusted net tangible book value would be $2.32 per share, with immediate dilution of $2.38 per share to new investors at an assumed price of $4.70.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for general corporate purposes, including product development and commercialization, R&D, administrative expenses, license or technology acquisitions, working capital, and capital expenditures.

• Management retains broad discretion over allocation; proceeds may also be used for debt repayment or acquisitions, though no current commitments exist.